A166 not checked

Kelun-Biotech

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
2 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
HER2-positive Breast Cancer, Her 2 Positive Breast Cancer
Main trialPhase 3
“Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy”In the company’s words, NCT06968585 on ClinicalTrials.gov

Other drugs for HER2-positive Breast Cancer

All 397 drugs for HER2-positive Breast Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Nov 2026 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Phase 2Recruiting 20 Sep 2027 A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 1/2Completed 12 Jan 2022 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1Completed 9 Apr 2026 A Study of A166 in Patients With Advanced Solid Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow A166

Following is part of Solo: you see every change to A166 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in